This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.

Incredible” results from the PATINA trial suggested a new standard of care for HER2, ER-positive metastatic breast cancer.

结直肠癌（CRC）是全球范围内发病率和死亡率较高的恶性肿瘤之一。HER2 基因扩增在 CRC 中的发生率仅为 3%～5%[1]，但与其预后密切相关，并已成为新的治疗靶点。随着新型 HER2 靶向治疗的出现，针对 HER2 ...

Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial Authors retain all ...

The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

CURE created a list of the top breast cancer stories of this year, including those focused on patient-reported outcomes and ...

Neoadjuvant SHR-A1811 showed similar pathologic complete response rates to the standard 4-drug regimen in patients with ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

Medical Dialogues team earlier reported that the company had received approval from the Subject Expert Committee SEC, which is functional under the Central Drug Standard Control Organisation (CDSCO) ...